Home / Health / J&J Psoriasis Pill Approved in China, Igniting Market Race
J&J Psoriasis Pill Approved in China, Igniting Market Race
27 Aug
Summary
- J&J's oral psoriasis pill, Icotrokinra, gained regulatory approval in China.
- The drug is expected to challenge existing injectable treatments.
- China's pharmaceutical market sees intensified competition for psoriasis therapies.
Johnson & Johnson announced on Thursday that its oral medication for psoriasis has been approved by China's drug regulator. This marks a significant step in the world's second-largest pharmaceutical market, intensifying competition among drugmakers.
The newly approved drug, Icotrokinra, is indicated for moderate-to-severe plaque psoriasis, a chronic autoimmune skin condition affecting over 8.4 million people in China. J&J highlighted its potential as a safe and effective oral treatment.
Analysts foresee blockbuster potential for Icotrokinra, anticipating it will capture substantial market share from existing injectable treatments. The approval places it alongside other therapies from competitors such as Bristol Myers Squibb and AbbVie, with further oral treatments in development by companies like Innocare Pharma and Takeda Pharmaceutical.
